≡

Multiplex Assay Kit for Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay)

PLAT; T-PA; t-plasminogen activator; Alteplase; Reteplase

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
EDTA plasma(n=5) 87-105 101
heparin plasma(n=5) 81-101 93

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
EDTA plasma(n=5) 98-105% 79-105% 80-102% 98-105%
heparin plasma(n=5) 98-105% 87-103% 84-102% 88-95%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:tPA) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Annals of Clinical & Laboratory Science Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment pubmed:28249913
Cellular Physiology and Biochemistry Defective Platelet Activation and Bleeding Complications upon Cholestasis in Mice pubmed:28441661
Journal of allergy and clinical immunology Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. pubmed:27826093
European Journal of Neuroscience Urokinase receptor and tissue plasminogen activator as immediate‐early genes in pentylenetetrazole‐induced seizures in the mouse brain Pubmed: 31587391
Phytomedicine Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway Pubmed: 32120245
Sci Rep Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis Pubmed:35013379
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPA525Ra01 Recombinant Tissue Plasminogen Activator (tPA) Positive Control; Immunogen; SDS-PAGE; WB.
EPA525Ra61 Eukaryotic Tissue Plasminogen Activator (tPA) Positive Control; Immunogen; SDS-PAGE; WB.
PAA525Ra01 Polyclonal Antibody to Tissue Plasminogen Activator (tPA) WB; IHC; ICC; IP.
MAA525Ra21 Monoclonal Antibody to Tissue Plasminogen Activator (tPA) WB; IHC; ICC; IP.
SEA525Ra ELISA Kit for Tissue Plasminogen Activator (tPA) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA525Ra Multiplex Assay Kit for Tissue Plasminogen Activator (tPA) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.